In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals

Eduardo Rigon Zimmer1,2,3†, Antoine Leuzy1,2†, Venkat Bhat4, Serge Gauthier1 and Pedro Rosa-Neto1,2*

Abstract

Hyperphosphorylation of the tau protein leading to the formation of neurofibrillary tangles (NFTs) is a common feature in a wide range of neurodegenerative diseases known as tauopathies, which include Alzheimer’s disease (AD) and the frontotemporal dementias (FTDs). Although heavily investigated, the mechanisms underlying the pathogenesis and progression of tauopathies have yet to be fully understood. In this context, several rodent models have been developed that successfully recapitulate the behavioral and neurochemical features of tau pathology, aiming to achieve a better understanding of the link between tau and neurodegeneration. To date, behavioral and biochemical parameters assessed using these models have been conducted using a combination of memory tasks and invasive methods such as cerebrospinal fluid (CSF) sampling or post-mortem analysis. Recently, several novel positron emission tomography (PET) radiopharmaceuticals targeting tau tangles have been developed, allowing for non-invasive in vivo quantification of tau pathology. Combined with tau transgenic models and micro-PET, these tracers hold the promise of advancing the development of theoretical models and advancing our understanding of the natural history of AD and non-AD tauopathies. In this review, we briefly describe some of the most important insights for understanding the biological basis of tau pathology, and shed light on the opportunity for improved modeling of tau pathology using a combination of tau-radiopharmaceuticals and animal models.

Keywords: Positron emission tomography, Tau molecular agents, Tau rodent models, Tauopathies

Introduction

Tau is a microtubule-associated protein (MAP) responsible for the maintenance and promotion of cell microtubule stability. In the human brain there are six tau isoforms generated by in or out exons splicing and expressed as three repeat (3R) and four repeat (4R) isoforms. In the normal human brain these isoforms are present at similar levels [1]. Several serine (Ser) and threonine (Thr) phosphate acceptor residues (almost 90 sites in the longest form of human tau) are the main regulators of tau functioning and are a target for a wide range of brain kinases involved in crucial signaling pathways owing to the high availability of these phosphorylation sites [2].

There are at least four key kinases regulating tau phosphorylation states: glycogen synthase kinase-3B (GSK3-B), cyclin-dependent kinase 5 (CDK5), cAMP-dependent protein kinase (PKA) and microtubule-associated regulatory kinase (MARK). In addition to mediating axonal cytoskeletal stability, tau is involved in axonal development—including axonogenesis, polarization, outgrowth and myelination [3]—as well as in neuronal plasticity and the integration of microtubule functions with interneuronal signaling pathways [3,4].

The fine-tuning of tau phosphorylation also depends on protein phosphatase activities, in particular protein phosphatase 2A (PP2A). The major phosphatase in the human brain [5], PP2A accounts for the overwhelming majority of tau dephosphorylation. In fact, tau homeostasis depends on kinase/phosphatase activities and is of vital importance for the maintenance of microtubule stability, dynamics, as well as neuronal viability (Figure 1a).
Seeding and spreading of tau pathology

Aberrant phosphorylation of tau leads to disruption of microtubule stability and neurodegeneration. Phosphorylation in the residues Ser199/Ser202/Thr205 (AT8), Thr212/Ser214/Thr217 (AT100), Thr231/235 (AT180) and Ser396/Ser404 (PHF-1) are invariably abnormal in pathological processes involving tau [6] (Figure 1b). Abnormally phosphorylated tau undergoes misfolding and aggregation, which constitutes a widespread feature among neurodegenerative diseases, including Alzheimer’s disease (AD) and Frontotemporal dementias (FTDs) [7,8].

In these diseases, the so-called tauopathies, tau deposits are commonly found in the cell bodies and neuronal dendrites, assuming a fibrillar conformation known as neurofibrillary tangles (NFTs) [9] (Figure 2a). In AD, NFT formation follows a well-characterized pattern of propagation, first described by Braak and Braak. The Braak staging follows the topographical evolution of the disease by means of six stages, which demonstrate the spread of tau pathology from the transentorhinal layer (I-II) toward limbic (III-IV) and isocortical areas (V-VI) [10]. Additionally, several studies have shown the degree of tau pathology to correlate with synaptic dysfunction and brain atrophy, as well as the severity of cognitive decline [11-13]. Importantly, while in AD tangles are constituted of equimolar 3R and 4R isoforms, FTD variants express predominantly 3R or 4R isoforms [14].

The main challenge with respect to defining the role of tau pathology in human neurodegenerative conditions is the co-existence of multiple pathology types. For example, in AD it is hard to develop theoretical models that allow for predictions regarding the evolution of tau pathology since amyloidosis is also present to an important degree. To overcome the effect of multiple pathologies, animal models expressing a single human tau mutation or displaying aberrant tau phosphorylation can be used as a method of choice to achieve an improved understanding of tau biology, pathology and the mechanisms underlying its spread throughout the brain.

Genetic and chemical models of tau pathology

The use of rodents for recapitulating human neurodegenerative diseases has been unquestionable in providing new insights at a mechanistic level, with various genetic and chemical models capable of mimicking different features of tau pathology [15]. More specifically, the majority of transgenic models are constructed based on tau pathogenic mutations from frontotemporal dementia with parkinsonism-17 (FTDP-17), producing 4R pathology [16-18]. In addition, transgenic models using non-mutated human truncated tau are able to recapitulate neurofibrillary degeneration [19]. Recent advances, aiming to better model neurodegenerative changes seen in AD, pieced together mutated human amyloid precursor protein (hAPP) and wild-type human tau (without pathogenic mutation), producing a model displaying amyloid plaques and NFTs containing both 3R and 4R isoforms [20].

Importantly, transgenic models expressing human tau are capable of reproducing NFT formation [21,22]. In contrast, genetic models lacking human tau expression such as p25-transgenic mice, which overexpress the human activator of CDK5 kinase, [23,24] and chemical-induced models [25,26] lead to hyperphosphorylated tau in brain regions rich in tau expression, but not to NFT formation (for review of tau rodent models see http://www.alzforum.org/research-models).

Tau models have been employed for analyzing mechanisms, pathophysiology, behavior, and also for testing novel therapeutic strategies. Currently, behavioral tasks, analyzed by several memory paradigms, such as the Morris water maze (spatial memory), object recognition task (recognition memory) and Y or T-maze (working
memory), have been correlated with cerebrospinal fluid levels of tau and phospho-tau. Similar to humans, animal cognition correlates with tau pathology quantified in post-mortem tissue [25,27-29]. However, in terms of assessing the role of tau burden on cognition, classic behavior-pathology correlation methods are of limited use due their invasiveness and intrinsic cross-sectional study designs. In contrast, Positron Emission Tomography (PET) using tau-imaging agents provides a unique opportunity to observe the progression of tau pathology non-invasively and longitudinally.

**Tau imaging agents**

Advances in radiopharmaceuticals have recently led to novel tau-imaging agents, including \[^{18}\text{F}]T807, \[^{18}\text{F}]T808, \[^{18}\text{F}]\text{THK523}, \[^{18}\text{F}]\text{THK5105}, \[^{18}\text{F}]\text{THK5115} \text{and} \[^{11}\text{C}]\text{PBB3}. In the following paragraphs, we briefly discuss the state-of-the-art of these compounds and what lies ahead.

\[^{18}\text{F}]\text{T807} \text{and} \[^{18}\text{F}]\text{T808} \text{probes show promising results for tracking tau pathology in early clinical studies. In addition, post-mortem autoradiography followed by immunohistochemistry shows co-localization between these radiopharmaceuticals and phospho-tau antibodies [30,31].}

\[^{18}\text{F}]\text{THK523} \text{(first-generation),} \[^{18}\text{F}]\text{THK5105} \text{and} \[^{18}\text{F}]\text{THK5117} \text{(second-generation) show high affinity for tau fibrils [32].} \[^{18}\text{F}]\text{THK523 shows specificity for tangles in studies conducted in transgenic mice models harboring only amyloid plaques or NFTs [33]. However, similarly to several} \[^{18}\text{F}]\text{tracers,} \[^{18}\text{F}]\text{THK523 shows an undesired high non-specific retention in white matter (WM) that may obscure cortical uptake. WM non-specific uptake reduces the diagnostic sensitivity of numerous imaging agents. To overcome this limitation, the second-generation of THK tracers,} \[^{18}\text{F}]\text{THK5105} \text{and} \[^{18}\text{F}]\text{THK5117, were optimized for higher NFT cortical uptake and less WM retention [34].}

The only tau radioligand labeled with carbon-11, \[^{11}\text{C}]\text{PBB3}, shows striking specificity for NFT detection in transgenic models overexpressing human tau mutation. Despite its structural similarities with \[^{11}\text{C}]\text{PiB}, the \[^{11}\text{C}]\text{PBB3 data obtained in transgenic mice support specificity for tau pathology. In humans,} \[^{11}\text{C}]\text{PBB3 shows cortical uptake consistent with Braak staging. Indeed, positive} \[^{11}\text{C}]\text{PBB3 and negative} \[^{11}\text{C}]\text{PiB characterized a cortico-basal syndrome patient [35]. These tracers hold the promise of allowing for the in vivo detection and tracking of tau pathology, and may prove of use in differentiating AD and non-AD tauopathies. However, it is not entirely clear whether a single tau-imaging agent will be useful to quantify pathology underlying the entire spectrum of tauopathies given the presence of molecular heterogeneity. For example, it is commonly known in PET literature that the interaction between an imaging agent and a molecular target (e.g. a protein) occurs only if the binding pocket is accessible to the imaging agent. Binding pocket availability...}
is highly dependent on the protein structural conformation, which can be absent if the protein assumes an unusual conformation. Consequently, the ability of tracers to bind to NFTs may be affected by different post-translational modifications such that a given radiotracer may be able to bind NFTs but not to other ultrastructural tau conformations, such as straight (SF) or randomly coiled filaments (RCFs). Additionally, tau expression as 3R and 4R isoforms can strongly modulate the availability of binding pockets, since these different isoforms can assume distinct structural conformations.

In this context, the combination of tau tracers and genetic manipulation to achieve transgenic rodent models expressing human tau with a given conformation/isoform may accelerate our understanding of the mechanisms subserving tau-mediated neurodegeneration and clinical progression across the spectrum of tauopathies.

**Tracking tau pathology in small animals**

Since only human tau protein assumes the structural conformation rendering NFTs, transgenic models expressing human tau are *sine-qua-non* for testing new imaging agents with high translation value for human diseases [9]. Further, a high degree of homology and functional similarity is observed between humans and rodents in brain areas recognized as predilection sites for tau pathology, including the hippocampus [36-38].

Tau transgenic models, combined with behavioral assessment and *in vivo* imaging using microPET stands as a unique strategy for establishing the clinico-pathological correlations needed for testing the efficacy of novel disease-modifying drugs. Additionally, *in vivo* tracking of tau pathology in transgenic rodent models will provide new insights with high translational value owing to the spatiotemporal pattern of propagation similar to that observed in human tauopathies [37] (Figure 2b). In addition to occupying an important role in the full validation of tau-imaging tracers, microPET has the potential to provide high-resolution dynamic images that will estimate the content of tau aggregates via pharmacokinetic analysis. Finally, microPET can deliver crucial information regarding tracer kinetics, requisite for both the development of novel tau radiopharmaceuticals and in the context of imaging analysis.

**Clinical utility**

It is expected that tau-imaging agents will contribute to the early diagnosis of tauopathies. In addition, these imaging agents will significantly expand our knowledge regarding the propagation of tau protein in the human brain as well as its relationships with clinical features of the various tauopathies. Given the numerous drugs aiming to halt the progression of tau pathology, it is also expected that these ligands will allow for the monitoring of treatment effects of novel anti-tau therapies (see review Giacobini et al. [39]). Yet, there remains a significant amount of research to be conducted in order to establish the advantages and limitations of tau-imaging agents. Indeed, well-controlled microPET studies in animal models are necessary for the validation and development of tau specific PET agents with less non-specific binding and favorable kinetics (Table 1).

**Table 1 Tau imaging agents: from basic to clinical applications**

| Basic research | Clinical applications |
|----------------|-----------------------|
| The combination of Tau imaging agents and transgenic models can allow for: | The use of Tau imaging agents in the clinical approach can allow for: |
| a) Non-invasive longitudinal tracking of tau pathology | a) Early diagnosis |
| b) Longitudinal assessment of behavior as a function of tau pathology | b) Differential diagnosis |
| c) Determination of pharmacokinetic properties | c) Follow-up of cognitive decline as function of tau pathology progression |
| d) Development of novel radiopharmaceuticals | d) Monitoring of treatment effectiveness of novel anti-tau and associated therapies |
| e) Development of theoretical models regarding progression of tau pathology | e) Development of theoretical models regarding tau pathology progression |
| f) Estimation of sample size and endpoints in the context of clinical trials | |

**Concluding remarks**

PET in tau transgenic models allows for longitudinal assessment and thus is ideally suited for following tau pathology progression and/or response to disease-modifying drugs. Simultaneously, the use of the same animal for PET imaging and behavioral assessments eliminates the between-subject variability and will provide key insights on the role of tau in neurodegeneration and associated cognitive decline. Finally, these results can rapidly be translated to human research, delivering novel therapeutic strategies, mechanistic insights, predictive models and biomarkers.

**Competing interest**

The authors declare that they have no competing interest.

**Authors’ contribution**

ERZ and AL drafted the manuscript and designed the figures. VB critically revised the manuscript. SG and PRN guided and supervised the work. All authors read and approved the final manuscript.
Acknowledgements

This work was supported by Canadian institutes of Health Research (CIHR) [MOP-11-51-31], Alzheimer's Association [NIRG-08-92090], Nussia & André Aisenstadt Foundation, and Fonds de la recherche en santé du Québec (chercheur boursier).

Author details
1 Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging, Douglas Mental Health University Institute, McGill University, 6875 La Salle Blvd - FBC room 3149, Montreal, QC, H4H 1R3, Canada. 2Department of Biochemistry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. 3Department of Psychiatry, McGill University, Montreal, Quebec.

Received: 9 December 2013 Accepted: 7 March 2014

Published: 15 March 2014

References

1. Williams DR: Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Int Med J 2006, 36:652–660.
2. Buee L, Buee-Scherer V, Delacourte A, Hof PF: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33:95–130.
3. Gendreau KL, Hall GF: Tangles, toxicity, and tau secretion in AD - New approaches to a vexing problem. Frontiers in Neuro 2013, 4:160.
4. Johnson GV, Stoothoff WH: Tau phosphorylation in neuronal cell function and dysfunction. J of Cell Sci 2004, 117:5721–5729.
5. Gong CX, Iqbal K: Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 2008, 15:3231–3238.
6. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathologica 2002, 103:26–35.
7. Spiers-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT: Tau pathophysiology in neurodegeneration: a tangled issue. Trends in Neurosci 2009, 32:150–159.
8. Mackenzie RJ, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kitl J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozenmurz AJ, Kumar-Singh S, Akiyama H, Babione A, Spins S, Dickson DW, Trojanowski JQ, Mann DM: Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica 2010, 119:1–4.
9. Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007, 8:663–672.
10. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239–259.
11. Amagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillar tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992, 42:631–639.
12. Hampel H, Burger K, Pruessner JC, Zirkowski R, DelBene JAR, Jernick M, Leningser G, Evans AC, Davies P, Moller HJ, Teipel SJ: Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Archives of Neurol 2005, 62:770–773.
13. Guillozet AL, Weintraub S, Mash DC, Mesulam MM: Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Archives of Neurol 2003, 60:279–276.
14. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW: Cortico basal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurosci 2011, 12:283–292.
15. Gotz J, Detera-Wadleigh S, Bohlman H, Le Y, Wieser A, Schonrock N, Itterm TM: A decade of tau transgenic animal models and beyond. Brain Pathol 2007, 17:91–103.
16. Goedert M, Spillantini MG: A century of Alzheimer’s disease. Science 2006, 314:777–781.
17. Platt TL, Revesz V, Murphy MP: Transgenic models of Alzheimer’s disease: better utilization of existing models through viral transgenesis. Biochimica et biophysica Acta 1932, 2013:1437–1448.
18. Nasreddine ZS, Logino M, Clark LN, Lamarche J, Miller BL, Lamontagne A, Zhukareva V, Lee VM, Wilhemsen KC, Geschwind DH: From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Annals of Neurol 1999, 45:704–715.
19. Zilko N, Filippic P, Koson P, Fialova L, Skraba R, Zilkova M, Rolkova G, Kontsekova E, Novak M: Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006, 580:3582–3588.
20. Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H: Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol 2014. In press.
21. de Calignon A, Polidoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopelina KJ, Pitsick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT: Propagation of tau pathology in a model of early Alzheimer’s disease. Neuroan 2012, 73:685–697.
22. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM: Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. The J of Neuroscience: the Off J of the Soc for Neurosci 2013, 10:1024–1037.
23. Ahljanian MK, Barrezaeta NK, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JF, Nelson RB, McNeil JD: Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 2000, 97:2010–2015.
24. Ban F, Nast R, Sobocinski G, Bozler RN, Lipinski WP, Callahan AJ, Pack A, Wang K, Walker LC: Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. The J of Comparative Neuro 2002, 446:257–266.
25. Zimmer ER, Kalinine E, Haga CB, Torrez VR, Souza DO, Muller AP, Portela LV: Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadic acid administration in rats. Curr Alzheimer Res 2012, 9:1182–1190.
26. Grunblatt E, Salkovic-Petriric M, Osmanovic J, Riederer P, Hoyer S: Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J of Neurochem 2007, 101:757–770.
27. Van der Jeugd A, Vermaereke B, Derisbourg M, Lo AC, Hamdane M, Blum D, Buee L, D’Hoore R: Progressive age-related cognitive decline in tau mice. J of Alzheimer’s Dis: JAD 2013, 37:777–788.
28. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tau mouse model. The J of Neurosci: the Off J of the Soc for Neurosci 2010, 30:16559–16566.
29. Carreras I, Mckee AC, Choi JK, Aytan N, Kowall NW, Jenkins BG, Dedeoglu A: R-flurbiprofen improves tau, but not ASS pathology in a triple transgenic model of Alzheimer’s disease. Brain Res 2013, 1541:115–127.
30. Chien DT, Bahri S, Sturdenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elazarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand (F-18)-T807. J of Alzheimer’s Dis: JAD 2013, 34:457–468.
31. Chien DT, Sturdenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, lerner AJ, Su MY, Elazarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-Tau radioligand (F-18)-T808. J of Alzheimer’s Dis: JAD 2014, 38:171–184.
32. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, Yoshikawa T, Arai H, Iwata R, Kudo Y, Yama O: Comparison of the binding characteristics of (18 F) T807 and other amyloid imaging tracers to Alzheimer’s disease pathology. European J of nuclear Med and Mol Imaging 2013, 40:125–132.
33. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Bamkim KH, Rowe CC,新政 CL, Kudo Y, Capponi R, Yama O, Willemagen VL: 18 F-T807: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain J Neuro 2011, 134:1089–1100.
34. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Willemagen VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yama O, Kudo Y: Novel 18 F-labeled arylnilino derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nuclear Med 2013, 54:1420–1427.
35. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Hijichi M: Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094–1108.

36. Bunsey M, Eichenbaum H: Conservation of hippocampal memory function in rats and humans. Nature 1996, 379:255–257.

37. Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM: A(β) accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. The Am J of Pathol 1977–1988, 2010;177.

38. Vogt BA, Paxinos G: Cytoarchitecture of mouse and rat cingulate cortex with human homologies. Brain Struct Funct 2014, 219:185–192.

39. Giacobini E, Gold G: Alzheimer disease therapy-moving from amyloid-beta to tau. Nature Rev Neurol 2013, 9:677–686.

doi:10.1186/2047-9158-3-6

Cite this article as: Zimmer et al.: In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Translational Neurodegeneration 2014 3:6.